Insulet (PODD) Reaffirms Q2, FY16 Guidance

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today reaffirmed its second quarter and full year 2016 guidance. A recent preferred provider communication by UnitedHealthcare regarding in-network DME insulin pumps is not expected to have a material impact on OmniPod System coverage nor on Insulet's financial results.

For the year ending December 31, 2016, the Company is reaffirming its revenue guidance of $330 to $350 million compared to 2015 revenue from continuing operations of $263.9 million1. This represents year-over-year revenue growth of approximately 30% at the mid-point of the range.

For the quarter ending June 30, 2016, the Company is reaffirming its revenue guidance of $81 to $84 million compared to second quarter 2015 revenue from continuing operations of $60.6 million1. This represents year-over-year revenue growth of over 35% at the mid-point of the range.

(Street sees Q2 EPS ($017) on revenue of $81.2 million and FY EPS of ($0.65) on revenue of $337 million.)

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• SB Financial Group (SBFG) Tops Q1 EPS by 1c
• Marten Transport (MRTN) Misses Q1 EPS by 2c